StoneX Group’s Novo Nordisk NVO Stock Holding History

StoneX Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$436K	Buy	+11,130	New	+$513K	0.02%	763
2024 Q4	–	Sell	-2,148	Closed	-$256K	–	914
2024 Q3	$256K	Buy	2,148 +715	+50%	+$95.4K	0.02%	522
2024 Q2	$205K	Buy	+1,433	New	+$190K	0.02%	567
2021 Q4	–	Sell	-98,554	Closed	-$4.73M	–	596
2021 Q3	$4.73M	Buy	98,554 +83,504	+555%	+$4.04M	0.68%	29
2021 Q2	$630K	Buy	+15,050	New	+$583K	0.09%	217
2017 Q3	–	Sell	-22,134	Closed	-$475K	–	298
2017 Q2	$475K	Buy	+22,134	New	+$447K	0.15%	211

Other funds holding NVO

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

StoneX Group's NVO Position: Q3 2026 in Review

StoneX Group opened a new position in Novo Nordisk (NVO) in Q3 2026: 11,130 shares worth $436K. The stake represents 0.02% of the portfolio and ranks #763 among its holdings. This is a return to the name: StoneX Group previously reported a position in NVO as recently as Q3 2024.

StoneX Group first reported a position in NVO in Q2 2017 and has held it in 6 quarters since. The position peaked at $4.73M in Q3 2021. 816 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

StoneX Group held 11,130 shares of Novo Nordisk worth $436K as of Q3 2026.
Novo Nordisk was a new StoneX Group position in Q3 2026.
Novo Nordisk made up 0.02% of StoneX Group's portfolio in Q3 2026, its #763 holding.
StoneX Group first reported a position in Novo Nordisk in Q2 2017 and has held it in 6 quarters since.
StoneX Group's Novo Nordisk position peaked at $4.73M in Q3 2021.
816 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.